The study was aimed at evaluating antitumor and immunomodulatory effects of liposomal vaccine composed of P5 human epidermal growth factor receptor 2 (HER2)/neu-derived peptide coupled to the surface of high-temperature nanoliposomes containing distearoylphosphocholine:distearoylphosphoglycerol:Chol:dioleoylphosphatidylethanolamine (DOPE) comprising monophosphoryl lipid A (MPL) adjuvant in HER2/neu overexpressing the breast cancer model. BALB/c mice bearing TUBO carcinoma were subcutaneously immunized with formulations containing 10 µg P5 peptide and 25 µg MPL three times with 2-week intervals. To determine immuno responses in immunized mice, the amount of released interferon-γ and IL-4 were measured by the enzyme-linked immunospot method and the flow cytometric analysis on the isolated splenocytes. The results demonstrated that tumor-bearing mice immunized with Lip/DOPE/MPL/P5 formulation had the most released interferon-γ and the highest cytotoxic T lymphocyte responses that led to the lowest tumor size and the longest survival time than those of other formulations. The results achieved by Lip/DOPE/MPL/P5 formulation could make it a suitable candidate to induce effective antigen-specific tumor immunity against breast cancer.

Additional Metadata
Keywords breast cancer, cyototoxic T cell response, HER2/neu protein, P5 peptide, peptide-conjugated nanoliposome, prophylactic vaccine
Persistent URL dx.doi.org/10.1002/jcb.27090, hdl.handle.net/1765/111870
Journal Journal of Cellular Biochemistry
Citation
Rastakhiz, S. (Saeedeh), Yazdani, M. (Mona), Shariat, S. (Sheida), Arab, A. (Atefeh), Momtazi-Borojeni, A.A. (Amir Abbas), Barati, N. (Nastaran), … Jaafari, M.R. (2018). Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. Journal of Cellular Biochemistry. doi:10.1002/jcb.27090